Company intelligence / Profile preview

3billion

Ownership: Private
Employees: ~58
Development stage: Commercial

Overview

3billion provides commercialized AI-driven genetic testing services for rare diseases globally, with over 62,000 genomes analyzed as of late 2024. The company is leveraging its large-scale genomic data and proprietary AI platforms to expand into rare disease drug discovery, with initial results from its AI drug development platform expected soon. No clinical-stage therapeutic candidates have been publicly disclosed as of June 2025.

Therapeutic areas: Rare Diseases
Modalities: Small molecule (for drug discovery)Diagnostic test (genetic testing)
Industry: Molecular Diagnostics

Partnerships

AstraZeneca Korea (collaboration on aHUS diagnosis)Multinational pharmaceutical company for patient diagnosis support

Beyond the preview

Go deeper on 3billion.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 3billion.

Explore the full profile